Marvel Biosciences Advances MB-204 Toward First-in Human Testing, Selects CMAX as Phase I Clinical Trial Site

· Financial Post

J. Roderick (Rod) Matheson, Chief Executive Officer
Email: [email protected]
Dr. Mark Williams, President and Chief Science Officer
Email: [email protected]
Tel: 403 770 2469
Website: www.marvelbiotechnology.com | Twitter/X | LinkedIn Read More

Visit somethingsdifferent.biz for more information.

Read full story at source